The price of MoonLake Immunotherapeutics (NASDAQ: MLTX) closed at $47.05 in the last session, up 3.16% from day before closing price of $45.61. In other words, the price has increased by $+1.44 from its previous closing price. On the day, 995195 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
We take a closer look at MLTX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 51.59 and its Current Ratio is at 51.59. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wolfe Research on February 15, 2024, initiated with a Outperform rating and assigned the stock a target price of $77.
On December 08, 2023, Citigroup started tracking the stock assigning a Buy rating and target price of $72.
On November 02, 2023, Stifel started tracking the stock assigning a Buy rating and target price of $74.Stifel initiated its Buy rating on November 02, 2023, with a $74 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 29 ’24 when Santos da Silva Jorge sold 4,740 shares for $55.89 per share. The transaction valued at 264,919 led to the insider holds 2,982,814 shares of the business.
Santos da Silva Jorge sold 56,065 shares of MLTX for $3,083,575 on Feb 28 ’24. The Chief Executive Officer now owns 2,987,554 shares after completing the transaction at $55.00 per share. On Feb 28 ’24, another insider, Reich Kristian, who serves as the Chief Scientific Officer of the company, sold 31,910 shares for $55.00 each. As a result, the insider received 1,755,050 and left with 2,925,573 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MLTX now has a Market Capitalization of 2.87B and an Enterprise Value of 2.36B.
Stock Price History:
Over the past 52 weeks, MLTX has reached a high of $64.98, while it has fallen to a 52-week low of $17.82. The 50-Day Moving Average of the stock is 56.19, while the 200-Day Moving Average is calculated to be 51.01.
Shares Statistics:
According to the various share statistics, MLTX traded on average about 466.35K shares per day over the past 3-months and 669.6k shares per day over the past 10 days. A total of 60.47M shares are outstanding, with a floating share count of 47.19M. Insiders hold about 21.27% of the company’s shares, while institutions hold 98.47% stake in the company. Shares short for MLTX as of Feb 15, 2024 were 6.61M with a Short Ratio of 14.18, compared to 6.89M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 10.94% and a Short% of Float of 20.78%.
Earnings Estimates
The company has 10 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.2 for the current quarter, with a high estimate of -$0.13 and a low estimate of -$0.3, while EPS last year was -$0.23. The consensus estimate for the next quarter is -$0.28, with high estimates of -$0.13 and low estimates of -$0.47.
Analysts are recommending an EPS of between -$0.52 and -$1.93 for the fiscal current year, implying an average EPS of -$1.19. EPS for the following year is -$1.8, with 10 analysts recommending between -$0.7 and -$2.87.
